AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05859750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
Study NCT05859750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
Study NCT05859750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Description: liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
Study NCT05859750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
Description: oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
Study NCT05552625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TADIOS
Description: TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
Study NCT05552625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
Study NCT06525675 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant Injectable Product
Description: 500 mg fulvestrant on days 1, 14, 28, and once monthly thereafter, administered intramuscularly.
Study NCT06525675 — intervention group
Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: 2.5 mg letrozole per day, administered orally (continuous treatment)
Study NCT06525675 — intervention group
Intervention type: DRUG
Intervention: Palbociclib 125mg
Description: orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication
Study NCT04907747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication
Study NCT05223114 — intervention group
Intervention type: OTHER
Intervention: Not applicable (N/A)
Description: Not applicable to this study
Study NCT05195944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Treatment
Description: The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day.
Study NCT05195944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching material
Description: The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit reflection tool
Description: The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue tool
Description: The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational session for GPs
Description: Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational session for GPs
Description: Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom assessment scale
Description: An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
Study NCT04985305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom assessment scale
Description: An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
Study NCT05047783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib Mesylate
Description: 3CL-protease inhibitor
Study NCT05047783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04495010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04495010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT05334004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository
Study NCT05747794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist
Study NCT05747794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel will be given as standard of care (chemotherapy)
Study NCT05747794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel will be given as standard of care (chemotherapy)
Study NCT05747794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching eftilagimod alpha
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DG3173
Study NCT05929703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HELP
Description: This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.
Study NCT05929703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAM-HELP
Description: Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.
Study NCT05244707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean style diet
Description: The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
Study NCT05244707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
Study NCT04486157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A012
Description: The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
Study NCT04486157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Akynzeo 300Mg-0.5Mg Capsule
Description: The subjects will be administrated Akynzeo by Orally with water.
Study NCT05037526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G System
Description: Continuous glucose monitoring system
Study NCT05037526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring blood glucose
Description: Standard Care
Study NCT05803408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free oats
Description: Early vs late introduction of gluten free oats
Study NCT05803408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gluten-free oats
Description: Early vs late introduction of gluten free oats
Study NCT06348550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberol® K
Description: Nutraceutical containing an association of Berberine Fitosoma® and Monacolin K MonaKoPure®
Study NCT06348550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05728515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104
Description: Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
Study NCT04352296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure
Description: Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
Study NCT04352296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard blood pressure
Description: Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
Study NCT05922657 — intervention group
Intervention type: DEVICE
Intervention: Cerene
Description: Real world use of Cerene.
Study NCT04390048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
Study NCT04390048 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
Study NCT05717478 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rhBMP-2-BBM
Description: Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
Study NCT05717478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss+Bio-Gide
Description: Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
Study NCT05766709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: NNC0194-0499 will be administered subcutaneously once weekly.
Study NCT05766709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.
Study NCT05766709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
Description: NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
Study NCT05766709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499/Semaglutide A (40/0.33mg/mL)
Description: NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
Study NCT05593055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
Study NCT05593055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
Study NCT05593055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
Study NCT05439668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic abdominal strengthening exercises
Description: Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
Study NCT05439668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive abdominal exercises program
Description: Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
Study NCT05151471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral edaravone
Study NCT05151471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT06495502 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview
Description: Semi-structured interviews by qualitative health researchers
Study NCT04562987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
Study NCT04562987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Control
Description: Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
Study NCT06335108 — intervention group
Intervention type: PROCEDURE
Intervention: General Anaesthesia
Description: Breast surgery is carried out under general anesthesia.
Study NCT06335108 — intervention group
Intervention type: PROCEDURE
Intervention: Local tumescent anaesthesia
Description: Breast surgery is carried out under local tumescent anesthesia.
Study NCT05681572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
Study NCT05681572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
Study NCT05681572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
Study NCT05292950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-MUC5AC
Description: single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
Study NCT05292950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by inhalation of nebulized solution
Study NCT06643312 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The Tethered Pelvic Assist Device (TPAD)
Description: a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
Study NCT04956042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosciclopirox
Description: Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
Study NCT04956042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosciclopirox + Cytarabine
Description: Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DG3173
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Study NCT02217826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Study NCT05364268 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic Test: Diagnostic Software as Medical Device
Description: AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.